{"transactions":[{"id":677365,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-24T20:05:04.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":2785,"price":13,"value":36205.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026."}],"balance_after":1147064,"source":{"system":"sec-edgar","filing":"0001193125-26-363567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526363567/ownership.xml","form_type":"4"}},{"id":677364,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-24T20:05:04.000Z","date":"2026-08-20","kind":"sale","planned":true,"acquired":false,"shares":19890,"price":12.6,"value":250614.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price."}],"balance_after":1149849,"source":{"system":"sec-edgar","filing":"0001193125-26-363567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526363567/ownership.xml","form_type":"4"}},{"id":800013,"issuer":{"id":3058,"kind":"organization","name":"IQVIA HOLDINGS INC.","symbol":"IQV"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T21:03:02.000Z","date":"2026-04-23","kind":"grant","planned":false,"acquired":true,"shares":1571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant."}],"balance_after":16946,"source":{"system":"sec-edgar","filing":"0001628280-26-027609","document":"wk-form4_1777323780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478242/000162828026027609/wk-form4_1777323780.xml","form_type":"4"}},{"id":867108,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T21:19:05.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":225400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":225400,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":225400},"source":{"system":"sec-edgar","filing":"0001193125-26-088269","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088269/ownership.xml","form_type":"4"}},{"id":867107,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-03T21:19:05.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":156400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":1169739,"source":{"system":"sec-edgar","filing":"0001193125-26-088269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088269/ownership.xml","form_type":"4"}},{"id":944472,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-07T21:05:54.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":34146,"price":9.21,"value":314484.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":1013339,"source":{"system":"sec-edgar","filing":"0001193125-26-006294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006294/ownership.xml","form_type":"4"}},{"id":971169,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":false,"shares":8557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025."}],"balance_after":0,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":8557},"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971168,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":false,"shares":49959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025."}],"balance_after":8557,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":49959},"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971167,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":true,"shares":8557,"price":6.83,"value":58444.31,"ownership":{"direct":true},"balance_after":1047485,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971166,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":5355,"price":9.59,"value":51354.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price."}],"balance_after":1038928,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971165,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":32832,"price":9.47,"value":310919.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price."}],"balance_after":1044283,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971164,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":49959,"price":9.49,"value":474110.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price."}],"balance_after":1077115,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":971163,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T21:09:29.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":true,"shares":49959,"price":6.83,"value":341219.97,"ownership":{"direct":true},"balance_after":1127074,"source":{"system":"sec-edgar","filing":"0001193125-25-317551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525317551/ownership.xml","form_type":"4"}},{"id":1165557,"issuer":{"id":3058,"kind":"organization","name":"IQVIA HOLDINGS INC.","symbol":"IQV"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-25T22:17:57.000Z","date":"2025-04-24","kind":"grant","planned":false,"acquired":true,"shares":1592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant."}],"balance_after":15375,"source":{"system":"sec-edgar","filing":"0001478242-25-000072","document":"wk-form4_1745619471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478242/000147824225000072/wk-form4_1745619471.xml","form_type":"4"}},{"id":1228398,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:41:19.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":196000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":196000,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":196000},"source":{"system":"sec-edgar","filing":"0000950170-25-032248","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032248/ownership.xml","form_type":"4"}},{"id":1228397,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-04T21:41:19.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":136000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":1077115,"source":{"system":"sec-edgar","filing":"0000950170-25-032248","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032248/ownership.xml","form_type":"4"}},{"id":1308014,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-07T22:19:54.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":26807,"price":12.18,"value":326509.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":941115,"source":{"system":"sec-edgar","filing":"0000950170-25-003012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025003012/ownership.xml","form_type":"4"}},{"id":1314725,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-01-03T21:30:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":7850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted  31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":0,"derivative":{"exercise_date":"2025-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":7850},"source":{"system":"sec-edgar","filing":"0000950170-25-001236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025001236/ownership.xml","form_type":"4"}},{"id":1314724,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-03T21:30:05.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":true,"shares":7850,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":967922,"source":{"system":"sec-edgar","filing":"0000950170-25-001236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025001236/ownership.xml","form_type":"4"}},{"id":1522104,"issuer":{"id":3058,"kind":"organization","name":"IQVIA HOLDINGS INC.","symbol":"IQV"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-09T21:06:13.000Z","date":"2024-05-07","kind":"grant","planned":false,"acquired":true,"shares":1047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant."}],"balance_after":13783,"source":{"system":"sec-edgar","filing":"0001478242-24-000079","document":"wk-form4_1715288757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478242/000147824224000079/wk-form4_1715288757.xml","form_type":"4"}},{"id":1596202,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-05T21:10:12.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":163929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":163929,"derivative":{"exercise_price":32.66,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":163929},"source":{"system":"sec-edgar","filing":"0000950170-24-025900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024025900/ownership.xml","form_type":"4"}},{"id":1596201,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-05T21:10:12.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":113586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":960072,"source":{"system":"sec-edgar","filing":"0000950170-24-025900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024025900/ownership.xml","form_type":"4"}},{"id":1685483,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-05T21:51:05.000Z","date":"2024-01-03","kind":"sale","planned":false,"acquired":false,"shares":19223,"price":29.46,"value":566309.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":846486,"source":{"system":"sec-edgar","filing":"0000950170-24-002516","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024002516/ownership.xml","form_type":"4"}},{"id":1692431,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-01-03T22:30:40.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":7848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted  31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":7850,"derivative":{"exercise_date":"2024-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":7848},"source":{"system":"sec-edgar","filing":"0000950170-24-001197","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024001197/ownership.xml","form_type":"4"}},{"id":1692430,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-03T22:30:40.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":7848,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":865709,"source":{"system":"sec-edgar","filing":"0000950170-24-001197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024001197/ownership.xml","form_type":"4"}},{"id":1895000,"issuer":{"id":3058,"kind":"organization","name":"IQVIA HOLDINGS INC.","symbol":"IQV"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T21:20:56.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":1063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant."}],"balance_after":12736,"source":{"system":"sec-edgar","filing":"0001478242-23-000075","document":"wf-form4_168392643994809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478242/000147824223000075/wf-form4_168392643994809.xml","form_type":"4"}},{"id":1973478,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T22:18:02.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":128631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":128631,"derivative":{"exercise_price":40.75,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":128631},"source":{"system":"sec-edgar","filing":"0001209191-23-015764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123015764/doc4.xml","form_type":"4"}},{"id":1973477,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-03T22:18:02.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":91036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":857861,"source":{"system":"sec-edgar","filing":"0001209191-23-015764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123015764/doc4.xml","form_type":"4"}},{"id":2060425,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-06T22:32:49.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":6673,"price":37.21,"value":248302.33,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023."}],"balance_after":766825,"source":{"system":"sec-edgar","filing":"0001209191-23-002425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123002425/doc4.xml","form_type":"4"}},{"id":2067634,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-01-05T01:36:01.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":7848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":15698,"derivative":{"exercise_date":"2023-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":7848},"source":{"system":"sec-edgar","filing":"0001209191-23-001495","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123001495/doc4.xml","form_type":"4"}},{"id":2067633,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-05T01:36:01.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":7848,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":773498,"source":{"system":"sec-edgar","filing":"0001209191-23-001495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123001495/doc4.xml","form_type":"4"}},{"id":2271975,"issuer":{"id":3058,"kind":"organization","name":"IQVIA HOLDINGS INC.","symbol":"IQV"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T21:02:26.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant."}],"balance_after":11673,"source":{"system":"sec-edgar","filing":"0001478242-22-000072","document":"wf-form4_165247564402913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478242/000147824222000072/wf-form4_165247564402913.xml","form_type":"4"}},{"id":2350339,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-05T02:07:02.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":59941,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":59941,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":59941},"source":{"system":"sec-edgar","filing":"0001209191-22-016537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016537/doc4.xml","form_type":"4"}},{"id":2350338,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2022-03-05T02:07:02.000Z","date":"2022-01-01","kind":"exercise","acquired":false,"shares":7848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":23546,"derivative":{"exercise_date":"2022-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":7848},"source":{"system":"sec-edgar","filing":"0001209191-22-016537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016537/doc4.xml","form_type":"4"}},{"id":2350337,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-05T02:07:02.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":40990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":765650,"source":{"system":"sec-edgar","filing":"0001209191-22-016537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016537/doc4.xml","form_type":"4"}},{"id":2350336,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-05T02:07:02.000Z","date":"2022-01-01","kind":"sale","acquired":false,"shares":2493,"price":112.255,"value":279851.715,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022."}],"balance_after":724660,"source":{"system":"sec-edgar","filing":"0001209191-22-016537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016537/doc4.xml","form_type":"4"}},{"id":2350335,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-05T02:07:02.000Z","date":"2022-01-01","kind":"exercise","acquired":true,"shares":7848,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."}],"balance_after":727153,"source":{"system":"sec-edgar","filing":"0001209191-22-016537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016537/doc4.xml","form_type":"4"}},{"id":2583575,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-02T00:21:27.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":15985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,458 shares as of September 1, 2021."}],"balance_after":11515,"derivative":{"exercise_price":18.3,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":15985},"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583574,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-02T00:21:27.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":28750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 31, 2020."}],"balance_after":0,"derivative":{"exercise_price":23.46,"expiration_date":"2028-03-20","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583573,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-31","kind":"exercise","acquired":false,"shares":37833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021."}],"balance_after":90000,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":37833},"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583572,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"exercise","acquired":false,"shares":27167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021."}],"balance_after":127833,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":27167},"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583571,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"exercise","acquired":false,"shares":11637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 30, 2021."}],"balance_after":212501,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":11637},"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583570,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":44735,"price":170,"value":7604950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":719305,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583569,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":15985,"price":18.3,"value":292525.5,"ownership":{"direct":true},"balance_after":764040,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583568,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":28750,"price":23.46,"value":674475.0,"ownership":{"direct":true},"balance_after":748055,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583567,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-31","kind":"sale","acquired":false,"shares":37833,"price":155,"value":5864115.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":719305,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583566,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-31","kind":"exercise","acquired":true,"shares":37833,"price":14.58,"value":551605.14,"ownership":{"direct":true},"balance_after":757138,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583565,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":216,"price":160.69,"value":34709.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.62 to $160.745, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":719305,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583564,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":725,"price":159.98,"value":115985.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.56 to $160.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":719521,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583563,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":2598,"price":159.18,"value":413549.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.49 to $159.465, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":720246,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583562,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":3123,"price":157.75,"value":492653.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.395 to $158.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":722844,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583561,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":4758,"price":156.96,"value":746815.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":725967,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583560,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":15567,"price":155.7,"value":2423781.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.31 to $156.305, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":730725,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583559,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":7428,"price":154.98,"value":1151191.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.31 to $155.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":746292,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583558,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":2334,"price":153.66,"value":358642.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.22 to $154.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":753720,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583557,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":2055,"price":152.81,"value":314024.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $153.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":756054,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583556,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"exercise","acquired":true,"shares":27167,"price":14.58,"value":396094.86,"ownership":{"direct":true},"balance_after":758109,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2583555,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-02T00:21:27.000Z","date":"2021-08-30","kind":"exercise","acquired":true,"shares":11637,"price":13.4,"value":155935.8,"ownership":{"direct":true},"balance_after":730942,"source":{"system":"sec-edgar","filing":"0001209191-21-054331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121054331/doc4.xml","form_type":"4"}},{"id":2590863,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-25T20:14:17.000Z","date":"2021-08-23","kind":"exercise","acquired":false,"shares":27139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 23, 2021."}],"balance_after":224138,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":27139},"source":{"system":"sec-edgar","filing":"0001209191-21-053305","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121053305/doc4.xml","form_type":"4"}},{"id":2590862,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-25T20:14:17.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":100,"price":153.52,"value":15352.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":719305,"source":{"system":"sec-edgar","filing":"0001209191-21-053305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121053305/doc4.xml","form_type":"4"}},{"id":2590861,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-25T20:14:17.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":8165,"price":153.08,"value":1249898.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.38 to $153.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price."}],"balance_after":719405,"source":{"system":"sec-edgar","filing":"0001209191-21-053305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121053305/doc4.xml","form_type":"4"}},{"id":2590860,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-25T20:14:17.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":18874,"price":151.54,"value":2860165.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.38 to $152.18, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price."}],"balance_after":727570,"source":{"system":"sec-edgar","filing":"0001209191-21-053305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121053305/doc4.xml","form_type":"4"}},{"id":2590859,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-25T20:14:17.000Z","date":"2021-08-23","kind":"exercise","acquired":true,"shares":27139,"price":13.4,"value":363662.6,"ownership":{"direct":true},"balance_after":746444,"source":{"system":"sec-edgar","filing":"0001209191-21-053305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121053305/doc4.xml","form_type":"4"}},{"id":2594876,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-20T22:14:06.000Z","date":"2021-08-19","kind":"exercise","acquired":false,"shares":22682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 19, 2021."}],"balance_after":251277,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":22682},"source":{"system":"sec-edgar","filing":"0001209191-21-052835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121052835/doc4.xml","form_type":"4"}},{"id":2594875,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T22:14:06.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":5963,"price":152.3,"value":908164.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.055 to $152.80, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price."}],"balance_after":719305,"source":{"system":"sec-edgar","filing":"0001209191-21-052835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121052835/doc4.xml","form_type":"4"}},{"id":2594874,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T22:14:06.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":6993,"price":151.56,"value":1059859.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.02 to $152.015, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price."}],"balance_after":725268,"source":{"system":"sec-edgar","filing":"0001209191-21-052835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121052835/doc4.xml","form_type":"4"}},{"id":2594873,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T22:14:06.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":9726,"price":150.46,"value":1463373.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.96, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 19, 2021 at each separate price."}],"balance_after":732261,"source":{"system":"sec-edgar","filing":"0001209191-21-052835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121052835/doc4.xml","form_type":"4"}},{"id":2594872,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T22:14:06.000Z","date":"2021-08-19","kind":"exercise","acquired":true,"shares":22682,"price":13.4,"value":303938.8,"ownership":{"direct":true},"balance_after":741987,"source":{"system":"sec-edgar","filing":"0001209191-21-052835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121052835/doc4.xml","form_type":"4"}},{"id":2745071,"issuer":{"id":3058,"kind":"organization","name":"IQVIA HOLDINGS INC.","symbol":"IQV"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-19T21:04:01.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":934,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant."}],"balance_after":10678,"source":{"system":"sec-edgar","filing":"0001478242-21-000036","document":"wf-form4_161886622846061.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478242/000147824221000036/wf-form4_161886622846061.xml","form_type":"4"}},{"id":2748644,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-16T00:50:02.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":15937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021."}],"balance_after":15937,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":15937},"source":{"system":"sec-edgar","filing":"0001209191-21-026891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121026891/doc4.xml","form_type":"4"}},{"id":2748643,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-16T00:50:02.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":10000,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-026891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121026891/doc4.xml","form_type":"4"}},{"id":2748642,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-16T00:50:02.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":15937,"price":13.88,"value":221205.56,"ownership":{"direct":true},"balance_after":719305,"source":{"system":"sec-edgar","filing":"0001209191-21-026891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121026891/doc4.xml","form_type":"4"}},{"id":2748641,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-16T00:50:02.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"balance_after":703368,"source":{"system":"sec-edgar","filing":"0001209191-21-026891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121026891/doc4.xml","form_type":"4"}},{"id":2761303,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-03T00:46:42.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":26041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested as to 106,250 shares as of April 1, 2021."}],"balance_after":273959,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":26041},"source":{"system":"sec-edgar","filing":"0001209191-21-024889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121024889/doc4.xml","form_type":"4"}},{"id":2761302,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-03T00:46:42.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 135,000 shares as of April 1, 2021."}],"balance_after":155000,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-21-024889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121024889/doc4.xml","form_type":"4"}},{"id":2761301,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-03T00:46:42.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":13895,"price":83,"value":1153285.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":693368,"source":{"system":"sec-edgar","filing":"0001209191-21-024889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121024889/doc4.xml","form_type":"4"}},{"id":2761300,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-03T00:46:42.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":26041,"price":13.4,"value":348949.4,"ownership":{"direct":true},"balance_after":707263,"source":{"system":"sec-edgar","filing":"0001209191-21-024889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121024889/doc4.xml","form_type":"4"}},{"id":2761299,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-03T00:46:42.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":24314,"price":84,"value":2042376.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":681222,"source":{"system":"sec-edgar","filing":"0001209191-21-024889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121024889/doc4.xml","form_type":"4"}},{"id":2761298,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-04-03T00:46:42.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":45000,"price":14.58,"value":656100.0,"ownership":{"direct":true},"balance_after":705536,"source":{"system":"sec-edgar","filing":"0001209191-21-024889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121024889/doc4.xml","form_type":"4"}},{"id":2806249,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2021-03-05T22:50:45.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":31394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"date","element":"transactionDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 31,394 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."}],"balance_after":31394,"derivative":{"underlying":"Common Stock","underlying_shares":31394},"source":{"system":"sec-edgar","filing":"0001209191-21-018323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121018323/doc4.xml","form_type":"4"}},{"id":2806248,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T22:50:45.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":188363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 3, 2021 with respect to 188,363 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":188363,"derivative":{"exercise_price":57.71,"expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":188363},"source":{"system":"sec-edgar","filing":"0001209191-21-018323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121018323/doc4.xml","form_type":"4"}},{"id":2871920,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":56718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 9, 2021."}],"balance_after":68516,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":56718},"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2871919,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-05","kind":"exercise","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 92,082 shares as of February 5, 2021."}],"balance_after":285453,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2871918,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":28043,"price":75,"value":2103225.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":660536,"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2871917,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":56718,"price":6.83,"value":387383.94,"ownership":{"direct":true},"balance_after":688579,"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2871916,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":881,"price":68.78,"value":60595.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.03, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 5, 2021 at each separate price."}],"balance_after":631861,"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2871915,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":14018,"price":67.86,"value":951261.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.52 to $68.345, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 5, 2021 at each separate price."}],"balance_after":632742,"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2871914,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":8043,"price":67.18,"value":540328.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.495, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 5, 2021 at each separate price."}],"balance_after":646760,"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2871913,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-10T01:36:01.000Z","date":"2021-02-05","kind":"exercise","acquired":true,"shares":40000,"price":13.4,"value":536000.0,"ownership":{"direct":true},"balance_after":654803,"source":{"system":"sec-edgar","filing":"0001209191-21-009083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121009083/doc4.xml","form_type":"4"}},{"id":2881891,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-03","kind":"exercise","acquired":false,"shares":67060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F19","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 95,000 shares as of February 1, 2021."}],"balance_after":17940,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":67060},"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881890,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-03","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021."}],"balance_after":110000,"derivative":{"exercise_price":22.78,"expiration_date":"2028-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881889,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021."}],"balance_after":160000,"derivative":{"exercise_price":22.78,"expiration_date":"2028-01-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881888,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 55,885 shares as of February 1, 2021."}],"balance_after":27500,"derivative":{"exercise_price":18.295,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881887,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021."}],"balance_after":85000,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881886,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020."}],"balance_after":125234,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881885,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":36858,"price":73,"value":2690634.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":614803,"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881884,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-03","kind":"exercise","acquired":true,"shares":67060,"price":13.88,"value":930792.8,"ownership":{"direct":true},"balance_after":651661,"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881883,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":30998,"price":72,"value":2231856.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":584601,"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881882,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-03","kind":"exercise","acquired":true,"shares":50000,"price":22.78,"value":1139000.0,"ownership":{"direct":true},"balance_after":615599,"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}},{"id":2881881,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":12745,"kind":"person","name":"LEONARD JOHN M","position":1,"cik":"0001563584","reported_name":"LEONARD JOHN M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-02-04T02:39:39.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":5475,"price":65.04,"value":356094.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.76 to $65.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":565599,"source":{"system":"sec-edgar","filing":"0001209191-21-007638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919121007638/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-04T02:39:39.000000Z,2881881"}